Leading contract manufacturer Piramal Pharma has approved a $80 million expansion for its sterile injectables facility in Lexington, Kentucky, the company said on September 30.
The investment has been financed through bank loans and internal accruals, and aims to enhance site’s capacity to meet rising demand, said the company.
Nandini Piramal, Chairperson, Piramal Pharma said, “This expansion represents a strategic investment in the future of Piramal Pharma. Filling the commercial manufacturing gap enables the Lexington site to access the rapidly expanding injectables market and establish itself as a key player in the segment.”
The Lexington facility offers a differentiated product through sterile injectables.
Piramal Pharma - a Contract Development and Manufacturing Organization (CDMO) player -
offers end‐to‐end solutions across a drug's life cycle.
According the the company, the addressable market of current pipeline of generic injectables is roughly $2.2 billion.
On September 30, the company said it had received an Establishment Inspection Report (EIR) with Zero observations for its manufacturing facility located at Ahmedabad.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
